Biohaven (BHVN) Equity Raise Called 'Opportunistic' at Wedbush

January 29, 2020 10:27 AM EST Send to a Friend
Wedbush analyst Laura Chico reiterated an Outperform rating and $75.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login